Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

288 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Health-related quality of life in multiple sclerosis: effects of natalizumab.
Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators. Rudick RA, et al. Among authors: lublin fd. Ann Neurol. 2007 Oct;62(4):335-46. doi: 10.1002/ana.21163. Ann Neurol. 2007. PMID: 17696126 Clinical Trial.
Clinical outcomes assessment in multiple sclerosis.
Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Rudick R, et al. Ann Neurol. 1996 Sep;40(3):469-79. doi: 10.1002/ana.410400321. Ann Neurol. 1996. PMID: 8797541 Review.
Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: reporting extended results from phase III clinical trials. National Multiple Sclerosis Society Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.
Goodkin DE, Reingold S, Sibley W, Wolinsky J, McFarland H, Cookfair D, Lublin F. Goodkin DE, et al. Ann Neurol. 1999 Jul;46(1):132-4. doi: 10.1002/1531-8249(199907)46:1<132::aid-ana22>3.0.co;2-z. Ann Neurol. 1999. PMID: 10401793 No abstract available.
Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators.
Wolinsky JS, Narayana PA, Noseworthy JH, Lublin FD, Whitaker JN, Linde A, Gjörstrup P, Sullivan HC. Wolinsky JS, et al. Among authors: lublin fd. Neurology. 2000 May 9;54(9):1734-41. doi: 10.1212/wnl.54.9.1734. Neurology. 2000. PMID: 10802777 Clinical Trial.
288 results